researchdrivelogo.jpg
Rising Demand for Animal Testing Alternatives for Drug Testing to Boost the Growth of the Global Organ on Chip Market by 2028 – Exclusive Report [180 Pages] By Research Dive
18 août 2021 09h02 HE | Research Dive
New York, USA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- As per a latest report published by Research Dive, the global organ on chip market is estimated to register a revenue of $697,654.3 thousand by 2028,...
researchdrivelogo.jpg
Rising Sepsis Cases Along with the Growing Prevalence of Infectious Disorders Expected to Surge the Growth of the Bloodstream Infection Testing Market by 2027 – Exclusive Report [247 Pages] By Research Dive
23 juin 2021 09h05 HE | Research Dive
New York, USA, June 23, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global bloodstream infection testing market is projected to register a revenue of $7,722.2...
ScipherTM.png
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
15 juin 2021 08h00 HE | Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
PRPO logo.png
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
10 mai 2021 10h30 HE | Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...
PRPO logo.png
Mr. Ron Andrews joins Precipio’s Board of Directors
03 mars 2021 13h00 HE | Precipio, Inc.
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the company’s Board of Directors. As...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing
08 déc. 2020 20h06 HE | Sorrento Therapeutics, Inc.
Sorrento receives Clinical Laboratory Improvement Amendments (CLIA) license from the State of California for clinical sample testingSorrento intends to initially offer three diagnostic tests for...
PRPO logo.png
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
22 sept. 2020 10h30 HE | Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...
PRPO logo.png
Precipio Launches New HemeScreen™ Reagent Rental Program
06 avr. 2020 10h00 HE | Precipio, Inc.
NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program....
PRPO logo.png
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
30 sept. 2019 11h10 HE | Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
PRPO logo.png
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
26 sept. 2019 10h53 HE | Precipio, Inc.
 Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...